SpinalCyte, LLC, a spinal technology company focused on autologous regrowth of the spinal disc nucleus using human dermal fibroblasts (HDFs), today announced the addition of Jeffrey Geesin, Ph.D. to its Clinical Advisory Board. Dr. Geesin, Former Director of Research & Development Advanced Technologies & Regenerative Medicine at Johnson & Johnson (JNJ), is one of the foremost authorities in the field of regenerative medicine.
“SpinalCyte’s technology has the potential to become a leader in the fast growing field of regenerative medicine. The SpinalCyte approach provides a simple solution to regrow the spinal disc and they can emerge as the standard of treatment for degenerative disc disease. Their technology can become a disruptive alternative to existing, much more invasive procedures,” remarked Dr. Geesin.
“We are excited to have an industry leader such as Dr. Geesin endorse our technology with his involvement on our Clinical Advisory Board. Dr. Geesin’s experience and knowledge of the clinical and business climate surrounding degenerative disc disease will provide SpinalCyte with a valuable resource as we move into our final animal trials and we view his involvement as a tremendous validation of our unique approach,” said Pete O’Heeron, Chief Executive Officer.
The nucleus pulposus is a gelatinous material that acts as a cushion or shock absorber to the spinal column. It functions to distribute hydraulic pressure in all directions within each disc under compressive loads. The nucleus pulposus consists of chondrocytes, collagen fibrils, and proteoglycan aggrecans.
About Jeffrey Geesin, Ph.D.
Dr. Geesin received his Ph.D. from Rutgers University. Upon graduation, Dr. Geesin joined Johnson & Johnson ascending to Director of Research and Development of Wound Healing Technologies. Over the next 15 years, Dr. Geesin held numerous senior positions within Johnson & Johnson and finished his career as the Director of Advanced Technologies and Regenerative Medicine. He currently maintains his own consulting business. Dr. Geesin has authored or coauthored 50 journal articles and has conducted over 75 presentations at scientific conferences. He is currently a member of the Wound Healing Society and the International Cartilage Repair Society.
About SpinalCyte, LLC
Based in Houston, Texas, SpinalCyte, LLC is a spinal technology company founded in 2007 for the purpose of developing an innovative and autologous solution for nucleus replacement using human dermal fibroblasts. The goal of SpinalCyte is to develop a nucleus regrowth technology using autologous dermal cells harvested from the patient. To date, SpinalCyte has been funded entirely by angel investors.Business Wire
Last updated on: 06/02/2013